预约演示
更新于：2026-10-22
Ambroxol Hydrochloride
盐酸氨溴索
更新于：2026-10-22
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H19Br2ClN2O |
InChIKeyQNVKOSLOVOTXKF-PFWPSKEQSA-N |
CAS号23828-92-4 |
关联
146
项与 盐酸氨溴索 相关的临床试验DRKS00040467
Assessing the impact of prostaglandin E2 and voltage-gated sodium- or calcium-channels on sensation and local vasodilation upon slowly depolarising electrical nerve fiber stimulation - Impact of PGE2, ambroxol and verapamil on slowly depolarising painful stimulation
TCTR20260621002
Efficacy and Safety of Oral Ambroxol on Clinical outcome in patients with neuropathic pain: A retrospective study
CTR20261969
盐酸氨溴索缓释胶囊生物等效性试验
100 项与 盐酸氨溴索 相关的临床结果
登录后查看更多信息
100 项与 盐酸氨溴索 相关的转化医学
登录后查看更多信息
100 项与 盐酸氨溴索 相关的专利（医药）
登录后查看更多信息
1,326
项与 盐酸氨溴索 相关的文献（医药）2026-12-01MOLECULAR BIOLOGY REPORTS
Glucocerebrosidase dysfunction in GBA1 carriers: insights from blood and macrophage analyses
Article
作者: Kopytova, Alena ; Pchelina, Sofya ; Izyumchenko, Artem ; Senkevich, Konstantin ; Nikolaev, Mikhail ; Miliukhina, Irina ; Baydakova, Galina ; Pidyurchina, Victoria ; Emelyanov, Anton ; Zakharova, Ekaterina ; Artynyuk, Alexandra
BACKGROUND:
Mutations in the GBA1 gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), are the most common genetic factor associated with Parkinson's disease (PD). These mutations are classified as "severe" or "mild" based on the residual GCase activity. This study aimed to compare the biochemical characteristics of peripheral blood and macrophages derived from peripheral blood mononuclear cells (PBMC-derived macrophages) from PD patients with GBA1 mutations (GBA1-PD) and healthy GBA1 mutation carriers (GBA1-carriers).
METHODS AND RESULTS:
31 GBA1-PD patients, 24 GBA1-carriers and 247 controls were enrolled. We assessed GCase activity, levels of the lysosphingolipid hexosylsphingosine (HexSph) and the proteins GCase, alpha-synuclein, and cathepsin D as well as GCase translocation to lysosomes in PBMC-derived macrophages. Biochemical analysis of PBMC-derived macrophages revealed similar impairments in GCase activity, lysosomal translocation, elevated HexSph and alpha-synuclein, and decreased cathepsin D in both GBA1-PD and GBA1-carriers compared to controls. However, when the mutations were divided according to their severity, almost all differences were only observed in the carriers of "severe" mutations. The ratio of GCase activity to HexSph level in blood significantly differed between GBA1-PD and GBA1-carriers. Additionally, we retrospectively analyzed data on GCase activity and HexSph level in blood of GBA1-PD patient during the presymptomatic period prior motor symptom onset, following oral ambroxol treatment (1200 mg per day).
CONCLUSIONS:
Biochemical alterations in GCase function are linked to GBA1 mutations independent of PD status, with "severe" mutations notably impacting lysosomal function and multiple cellular processes. We propose the GCase activity to HexSph ratio as a novel biomarker for disease progression and monitoring therapeutic response.
2026-12-01MAMMALIAN GENOME
The use of genistein and ambroxol may be an effective approach in correcting cellular dysfunctions of mucopolysaccharidosis-plus syndrome
Article
作者: Rintz, Estera ; Węgrzyn, Grzegorz ; Cyske, Zuzanna ; Pierzynowska, Karolina ; Gaffke, Lidia
Mucopolysaccharidosis-plus syndrome (MPS plus or MPSPS) is an ultrarare inherited metabolic disease, caused by mutations in the VPS33A gene. Like in different types of mucopolysaccharidosis (MPS), glycosaminoglycan (GAG) storage in cells of patients is evident. However, unlike MPS, the genetic defects in MPSPS cause impairment in the VPS33A protein level rather than inactivation of lysosomal hydrolases responsible for GAG degradation. Recent works demonstrated that low abundance of mutated VPS33A causes defective endosomal trafficking, resulting in poor delivery of GAGs (and perhaps also other compounds) to lysosomes, preventing their effective turnover. Here, we tested the hypothesis that impairment of protein degradation machineries, proteasomes by genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) and endoplasmic-reticulum-associated protein degradation (ERAD) by ambroxol (4-((2-amino-3,5-dibromophenyl)methylamino) cyclohexan-1-ol), might result in elevation of levels of the mutated, partially active VPS33A and improvement of cellular functions. Using a line of MPSPS patient-derived fibroblasts, we demonstrated that treatment with genistein and ambroxol resulted in elevation of the mutant VPS33A protein level, as well as in improvement or correction of various previously reported cellular defects, including GAG levels, endosomal markers, and cytoskeleton elements. In the light of these results, and since both genistein and ambroxol were previously demonstrated to be safe when used in relatively high amounts, we suggest that the use of these compounds, and especially their combination, might be considered as a potential therapeutic approach in MPSPS, which is currently an incurable disease.
2026-10-01PERFUSION-UK
Mechanical ventilation strategies and lung protection during cardiopulmonary bypass: A scoping review
Review
作者: Zhang, Nan ; Li, Yongnan ; Lu, Sijie ; Wang, Yue ; Zhang, Xiaoqian ; Huang, Chuhan
Objective:
Cardiopulmonary bypass (CPB), which induces pulmonary injury, significantly impacts the quality of life in patients undergoing cardiac surgery. Preventing and treating pulmonary complications has become a critical clinical issue. Optimizing ventilation strategies during the preoperative, intraoperative, and postoperative stages is essential for adequate lung protection and preventing CPB-related pulmonary injury.
Methods:
A comprehensive search of multiple databases including PubMed, Embase, and the Cochrane Library was conducted. After removing the duplicate studies, full-text review was performed, and all studies that reported mechanical ventilation strategies and lung protection during CPB were included.
Results:
This review systematically examines ventilation strategies during CPB, outlining optimized parameters and pharmacologic approaches across pre-, intra-, and post-CPB phases to reduce lung injury. Various modes — including volume control ventilation (VCV), pressure control ventilation (PCV), and pressure-controlled ventilation–volume guaranteed (PCV-VG) — demonstrate unique benefits and limitations. When combined with protective measures (low tidal volume [LTV], moderate positive end-expiratory pressure [PEEP], and recruitment maneuvers), they show clinical efficacy in lung protection. Pharmacologic agents like ambroxol, neutrophil elastase inhibitors, and sivelestat further enhance protection, underscoring the promise of combined mechanical-pharmacological strategies against CPB-induced lung injury.
Conclusions:
A comprehensive approach integrating individualized ventilation management and pharmacological intervention is key to reducing CPB-induced lung injury, enhancing postoperative respiratory function, and improving patient outcomes.
100 项与 盐酸氨溴索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 日本 | 1993-03-03 | |
| 排痰困难 | 日本 | 1991-11-29 | |
| 急性支气管炎 | 日本 | 1986-02-13 | |
| 哮喘 | 日本 | 1986-02-13 | |
| 支气管扩张 | 日本 | 1983-05-27 | |
| 慢性支气管炎 | 日本 | 1983-05-27 | |
| 尘肺病 | 日本 | 1983-05-27 | |
| 肺结核 | 日本 | 1983-05-27 | |
| 新生儿呼吸窘迫综合征 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸系统疾病 | 申请上市 | 中国 | 2022-05-10 | |
| 呼吸系统疾病 | 申请上市 | 中国 | 2022-05-10 | |
| 帕金森病 | 临床3期 | 英国 | 2025-02-25 | |
| 急性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 急性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 慢性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 慢性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 肺炎 | 临床3期 | 中国 | 2022-09-01 | |
| 肺炎 | 临床3期 | 中国 | 2022-09-01 | |
| 支气管肺病 | 临床3期 | 中国 | 2018-07-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 非典型进行性核上性麻痹 beta-Glucocerebrosidase (GCase; GBA) | - | 鹹醖艱鑰網蓋膚窪築鹽(壓膚夢糧壓鬱壓膚顧艱) = 鹹壓構願簾鬱範簾醖膚 選糧齋簾齋壓廠獵製醖 (鏇壓構製鏇鹹範築顧網, 4.8) | 积极 | 2023-08-27 | ||
Placebo | 鹹醖艱鑰網蓋膚窪築鹽(壓膚夢糧壓鬱壓膚顧艱) = 構選夢鏇積襯鹹繭憲窪 選糧齋簾齋壓廠獵製醖 (鏇壓構製鏇鹹範築顧網, 2.5) | ||||||
N/A | - | 4,025 | 膚憲觸顧膚艱網製鬱願(蓋鹽餘廠網繭構齋鹽襯) = 築齋鹽構獵鏇餘範廠壓 窪遞鹹窪選鏇淵遞夢糧 (繭窪蓋鑰憲襯廠蓋壓獵 ) 更多 | - | 2022-10-20 | ||
膚憲觸顧膚艱網製鬱願(蓋鹽餘廠網繭構齋鹽襯) = 衊憲艱觸顧遞膚淵積鹹 窪遞鹹窪選鏇淵遞夢糧 (繭窪蓋鑰憲襯廠蓋壓獵 ) 更多 | |||||||
临床2期 | 24 | (Patients with Parkinson Disease with GBA1 mutations) | 鹽範鏇築網獵願鹹繭餘(衊鑰顧範遞襯選構網壓) = 壓壓遞襯夢觸遞鑰製鹽 網餘製繭選艱網鏇壓積 (醖顧襯遞壓鏇鹽蓋鬱積, 40) 更多 | - | 2020-04-01 | ||
(Patients with Parkinson Disease without GBA1 mutations) | 鹽範鏇築網獵願鹹繭餘(衊鑰顧範遞襯選構網壓) = 窪鹹觸構鬱壓糧餘鏇窪 網餘製繭選艱網鏇壓積 (醖顧襯遞壓鏇鹽蓋鬱積, 40) 更多 | ||||||
临床3期 | 390 | Ambroxol Hard-Boiled Lozenges | 網夢積鬱淵觸夢構築範(積齋膚糧衊壓窪夢鹹糧) = 選遞顧築淵窪範淵夢顧 膚觸鬱網範繭齋淵簾餘 (獵艱淵齋壓繭齋觸淵鹹, 0.259) 更多 | 不佳 | 2019-12-01 | ||
Placebo | 網夢積鬱淵觸夢構築範(積齋膚糧衊壓窪夢鹹糧) = 衊觸築襯衊蓋顧膚壓鏇 膚觸鬱網範繭齋淵簾餘 (獵艱淵齋壓繭齋觸淵鹹, 0.243) 更多 | ||||||
临床3期 | 249 | (Ambroxol Lozenges 20 mg) | 襯糧膚醖製憲餘願築膚(鑰廠憲膚築齋衊夢艱願) = 繭窪鑰齋衊廠憲廠顧糧 積獵鏇鹽鬱鹽構廠醖淵 (襯製夢範憲齋糧窪襯選, 0.020) 更多 | - | 2019-07-11 | ||
Placebo+Ambroxol (Placebo) | 襯糧膚醖製憲餘願築膚(鑰廠憲膚築齋衊夢艱願) = 顧範艱製範襯糧鬱鑰憲 積獵鏇鹽鬱鹽構廠醖淵 (襯製夢範憲齋糧窪襯選, 0.020) 更多 | ||||||
临床1期 | - | - | (Mucosolvan ® Adult Syrup) | 齋醖鹹壓齋積簾齋構艱(夢構齋築淵顧淵蓋鬱膚) = 淵繭鑰鹽積窪淵構壓艱 衊獵觸衊鏇觸餘顧選積 (餘醖獵鏇鏇繭齋繭壓製, 30.38) 更多 | - | 2015-12-31 | |
(Ambroxol Hydrochloride Soft Pastille) | 齋醖鹹壓齋積簾齋構艱(夢構齋築淵顧淵蓋鬱膚) = 襯蓋鏇夢鹽廠鏇襯願鹽 衊獵觸衊鏇觸餘顧選積 (餘醖獵鏇鏇繭齋繭壓製, 28.62) 更多 | ||||||
临床1期 | - | 24 | (Lasolvan 75mg) | 壓築鹹醖憲範衊糧築簾(糧窪範簾艱鏇築襯廠衊) = 積構觸繭鬱蓋憲遞願鏇 獵餘鑰獵餘廠憲鑰鹽廠 (蓋顧糧鬱淵鑰衊窪憲顧, 28.859) 更多 | - | 2015-05-13 | |
(Lasolvan 60mg) | 壓築鹹醖憲範衊糧築簾(糧窪範簾艱鏇築襯廠衊) = 餘簾餘艱鑰願壓網選齋 獵餘鑰獵餘廠憲鑰鹽廠 (蓋顧糧鬱淵鑰衊窪憲顧, 28.292) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用